AI Segmentation Software for Radiation Therapy Planning Introduced in Canada
MVision AI’s guideline-based AI segmentation, GBAIS, will now be available in Canada after the company signed a new distribution partnership with Medron Medical Systems, subject to approval from Health Canada.
The collaboration authorizes Medron Medical Systems to distribute products and services of MVision AI throughout Canada. Medron Medical Systems and MVision AI are devoted to helping oncology departments receive exceptional and consistent radiotherapy machine learning solutions across Canada. MVision AI’s specialists will be collaborating with Medron Medical System Inc.’s experts to undertake the distribution of the finest, most convenient, and consistent radiotherapy services.
“Innovation and the introduction of new modalities in radiation oncology have changed the landscape in how radiation therapy is delivered. The introduction of artificial intelligence (AI) in treatment planning is the beginning of a new era that will ultimately lead to greater accuracy in radiation dose delivery, leading to improved patient outcomes,” said Ronald Wallace, President of Medron Medical Systems Inc.
“Medron Medical Systems Inc. is proud to partner with MVision in developing the Canadian market of their Automatic Segmentation platform using their unique AI algorithms.”
As stated by MVision AI’s CEO and Co-Founder, Mahmudul Hasan, “MVision is continuing its rapid expansion. We are excited to start this partnership with Medron Medical Systems Inc. for Canadian hospitals. We are well ahead of our mission to serve radiotherapy patients with fast and high-quality treatment plans.”
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval